Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Lupin Limited, together with its subsidiaries, operates as a pharmaceutical company in India and internationally. It engages in the drug discovery, development, production, marketing, and sale of various branded and generic formulations, biosimilars, over-the-counter and specialty drugs, and active pharmaceutical ingredients (APIs). The company offers formulations for use in the therapeutic areas of anti-tuberculosis, diabetes management, cardiovascular, chronic obstructive pulmonary diseases, asthma, gynecology and women's health, central nervous system, oncology, immunology, genomics, metabolic disorders, dermatology, urology, pediatrics, gastrointestinal, anti-infective, and nonsteroidal anti-inflammatory drug therapies, as well as engages in the bio clinical research activities. It operates through network consists of labs, LupiMitra collection centers, and pick-up points. The company was formerly known as Lupin Chemicals Limited and changed its name to Lupin Limited in 2001. Lupin Limited was founded in 1968 and is headquartered in Mumbai, India.

Revenue projections:

Revenue projections for LUPIN
Revenue projections for LUPIN

Revenues for Lupin Limited are expected to drop compared to the previous year, which could be a cause for concern for investors. A decline in earnings may negatively impact the company's profitability, leading cautious investors to reconsider their positions, as it often signals challenges in overall financial health.

Financial Ratios:

currentRatio 0.000000
forwardPE 20.870016
debtToEquity 31.500000
earningsGrowth 0.519000
revenueGrowth 0.133000
grossMargins 0.683230
operatingMargins 0.223940
trailingEps 71.600000
forwardEps 81.760000

LUPIN's Forward PE is at a healthy level, meaning the stock price is aligned favorably with earnings. This suggests that the stock isn't overpriced, providing room for growth and making it an appealing option for investors looking to capitalize on potential future gains.
LUPIN's positive earnings and revenue growth indicate that the company is expected to continue expanding its business. These trends reflect strong financial health, with increasing profits and sales suggesting sustained growth and success for LUPIN.
Lupin Limited's positive gross and operating margins indicate strong financial performance. These margins show that the company is profitable and efficient in its operations, with effective cost control contributing to its overall financial success.
Lupin Limited's forward EPS surpasses its trailing EPS, reflecting expectations of higher profitability in the current year. This suggests that Lupin Limited is projected to generate stronger earnings, indicating an optimistic financial outlook compared to the prior year's results.

Price projections:

Price projections for LUPIN
Price projections for LUPIN

Lupin Limited's price projections have been consistently revised upward, suggesting that analysts are becoming increasingly optimistic about the company's future. This trend reflects confidence in Lupin Limited's ability to achieve strong financial results.

Recommendation changes over time:

Recommendations trend for LUPIN
Recommendations trend for LUPIN


The recent buy bias for LUPIN from analysts signals strong confidence in the stock's potential. This positive sentiment could encourage investors to see LUPIN as a smart place to invest their money, especially those looking for stable, long-term returns in a well-established company.